Related by context. All words. (Click for frequent words.) 68 Alzhemed TM 67 OvaRex R 67 OvaRex ® MAb 66 phase IIa clinical 66 Factor VIIa 65 Troxatyl 65 Cx# [002] 65 Cloretazine 65 Dacogen injection 64 Annamycin 64 atacicept 64 HQK 64 Memryte 64 Trofex TM 64 seliciclib CYC# 64 Amrubicin 64 EP #R 64 isoform selective 64 Phase IIb clinical trials 64 SinuNase TM 64 IMA# 64 PDE# inhibitors 64 targeted radiotherapeutic 64 tramiprosate Alzhemed TM 64 phase IIb clinical 64 Solazed 64 ELACYT 64 Shigamabs ® 64 TBC# 63 Panzem 63 ATL# [001] 63 PDX pralatrexate 63 Pradefovir 63 Zybrestat 63 SinuNase ™ 63 YONDELIS 63 Xanafide 63 Trofex 63 CEQ# 63 Archexin 63 DOS# 63 Mipomersen 63 Onconase 63 Aflibercept 63 Panzem R NCD 63 Cloretazine R VNP#M 63 Phase III randomized controlled 63 pan HDAC inhibitor 63 PLK1 SNALP 63 SMT C# 63 Cloretazine R 63 CB2 selective receptor agonist 63 depsipeptide 63 PRT# 63 AVN# [001] 63 mitogen activated ERK kinase 63 Daclizumab 63 JAK inhibitor 62 INCB# [001] 62 metaglidasen 62 Cloretazine ® 62 Luteinizing Hormone Releasing Hormone 62 Romidepsin 62 IV Busulfex 62 Dendreon investigational 62 Pimavanserin 62 volociximab 62 BZL# 62 anti CD3 monoclonal 62 EOquin 62 Cannabinor 62 Maxy G# 62 Tumour Vascular Disrupting Agent 62 Curaxin 62 HuLuc# 62 Campath ® 62 multicenter Phase II 62 MAb therapy 62 Androxal TM 62 PDE4 inhibitor 62 forodesine 62 Squalamine 62 Insegia 62 R roscovitine 62 novel VDA molecule 62 Proxinium TM 62 alemtuzumab Campath 62 Fx #A 62 YONDELIS R 62 radiation sensitizer 62 cannabinor 62 CRD5 62 Allovectin 7 62 Atiprimod 62 OvaRex 62 bardoxolone 62 Alocrest 62 RhuDex ® 62 ASONEP ™ 62 AEG# 62 alvespimycin 62 MKC# MT 62 ANYARA 62 CRLX# 62 Phase #b/#a clinical 62 VitiGam 62 XL# XL# 62 Evoltra 62 AQ4N 61 therapeutic monoclonal antibody 61 Zemiva TM 61 Sudhir Agrawal D.Phil 61 pharmacological chaperone 61 CR# vcMMAE 61 proteasome inhibitor 61 Thiarabine 61 Neuradiab 61 novel histone deacetylase 61 Davanat 61 Velcade bortezomib 61 Bezielle 61 MAXY G# 61 EndoTAG 61 Virulizin R 61 midstage clinical 61 XYOTAX TM 61 vascular disrupting agents 61 Pertuzumab 61 vidofludimus 61 OXIGON TM 61 pain palliation 61 PNP inhibitor 61 pharmacokinetic PK study 61 ALN PCS 61 LHRH antagonist 61 Akt inhibitor 61 Solazed TM 61 IRX 2 61 Azedra TM 61 Onalta ™ 61 Immunotherapeutic 61 brivaracetam 61 ARRY # 61 Silodosin 61 Aplidin 61 Simponi golimumab 61 Plicera 61 PEG SN# 61 Evoltra ® 61 Tarmogen 61 glucokinase activator 61 EndoTAGTM 1 61 KRN# 61 Clavis Pharma 61 trastuzumab DM1 61 thetreatment 61 Temsirolimus 61 TELINTRA R 61 Nicole Onetto MD 61 metastatic castration resistant 61 Amigal 61 OXi# 61 SNT MC# 61 Personalized Immunotherapy 61 THR beta agonist 61 omacetaxine mepesuccinate 61 fipamezole 61 TELINTRA 61 R#/MEM # 61 Soliris TM eculizumab 61 Diamyd ® 61 incyclinide 61 BrachySil ™ 61 GRN# 61 PSMA ADC 61 mertansine 61 Phase 1b clinical trials 61 EGS# 61 Allovectin 7 R 61 CYT# vascular disrupting 61 IL# PE#QQR 61 MOZOBIL 61 liposomal formulation 61 EndoTAG TM -1 61 TOCOSOL R 61 MAGE A3 ASCI 61 ularitide 61 thalidomide Thalomid 61 Degarelix 61 SYN# 61 Pyridorin 61 PI3K/Akt pathway inhibitor 61 Omnitarg 61 PSN# [002] 61 hypoxia activated prodrug 60 Spiegelmer ® 60 Lupuzor 60 candidate REP# 60 CCR9 antagonist 60 trastuzumab DM1 T DM1 60 Ocrelizumab 60 Aviptadil 60 Soliris eculizumab 60 romidepsin novel 60 Panzem R 60 obatoclax 60 Proellex TM 60 Virulizin ® 60 pradefovir 60 epigenetic therapies 60 Prednisporin 60 M# rationally 60 PF # [002] 60 molecular imaging radiopharmaceutical 60 CCX# 60 targeted antifolate 60 Phase 2a clinical trials 60 PORxin TM 60 PS# [001] 60 elvucitabine 60 CYT# potent vascular disrupting 60 non nucleoside inhibitor 60 relapsed leukemia 60 essential thrombocythemia ET 60 Revlimid lenalidomide 60 CDP# 60 receptor tyrosine kinase inhibitor 60 RhuDex 60 deforolimus 60 Albugon 60 oral picoplatin 60 metastatic carcinoid 60 beta 1a 60 delivers fluocinolone acetonide FA 60 IAP inhibitors 60 Panzem ® 60 polycythemia vera essential thrombocythemia 60 Hedgehog antagonist 60 Apokyn ® 60 RhuDex TM 60 TRO# 60 Phase Ib II 60 elotuzumab 60 GVAX ® 60 TÎ ² 4 60 tubulin inhibitor 60 Myocet 60 Fibrillex TM 60 Safinamide 60 ALK inhibitor 60 small molecule tyrosine 60 IMiDs R 60 Symadex 60 oral antiviral 60 metastatic hormone refractory 60 generation purine nucleoside 60 otelixizumab 60 terlipressin 60 CMV vaccine 60 metastatic colorectal 60 drug GLPG# 60 PSN# [001] 60 lintuzumab SGN 60 GRNVAC1 60 fostamatinib 60 castrate resistant prostate cancer 60 Shigamabs R 60 personalized immunotherapy 60 Peginterferon alfa 2b 60 HuMax CD4 60 Ceplene TM 60 TASQ 60 orally administered inhibitor 60 KSP inhibitor 60 Fodosine 60 vosaroxin 60 Angiocept 60 FOLOTYN ® 60 BiTE antibody 60 aurora kinase 60 ATL/TV# 60 TLK# 60 AMPK activators 60 nalbuphine ER 60 BRAF mutant 60 ASONEP TM 60 Unit Dose Budesonide 60 budesonide foam 60 leukemia AML 60 trial evaluating PRX# 60 torezolid phosphate 60 LymphoStat B TM 60 compound AEZS 60 DDP# 60 AFREZZA TM 60 histamine dihydrochloride 60 reslizumab 60 MAP# 59 radiotherapeutic 59 Tarceva TM 59 Phase IIIb clinical 59 Iluvien TM 59 PrevOnco 59 Canvaxin 59 Phase #/#a trial 59 rNAPc2 59 HuMax TAC 59 Amgen Neulasta ® 59 immune modulating 59 psoriasis rheumatoid arthritis 59 OncoVEX GM CSF 59 novel anticancer 59 phase IIa 59 acetonide FA 59 StemEx R 59 TOCOSOL 59 ELND-#/AZD-# 59 ospemifene 59 ILUVIEN ® 59 Iluvien ® 59 Prednisporin TM 59 CTAP# Capsules 59 Canvaxin TM 59 Zemiva ™ 59 elacytarabine 59 Guanilib 59 EndoTAG TM 59 humanized anti 59 dacetuzumab 59 mGluR2 NAM 59 oral anti arrhythmic 59 Behcet uveitis 59 lexidronam injection 59 triphendiol 59 ALTROPANE R 59 MEK inhibitor 59 Aryplase 59 epothilones 59 multi kinase inhibitor 59 histone deacetylase HDAC inhibitor 59 Cetrorelix 59 CBLC# 59 Asentar 59 MKC# MKC# PP 59 Acetavance TM intravenous acetaminophen 59 rxRNA 59 amrubicin 59 TransMID 59 Omacetaxine 59 NeoLipid R 59 Nexavar ® 59 HDAC Inhibitor 59 BrachySil TM 59 CCR5 antagonist 59 targeting CD# 59 Nexavar sorafenib 59 UPLYSO 59 chronic thromboembolic pulmonary 59 demonstrated antitumor activity 59 inhaled AAT 59 Ozarelix 59 Oxypurinol 59 EVIZON TM 59 NP2 Enkephalin 59 kidney urologic 59 rhMBL 59 GW# [003] 59 Vernalis plc 59 KIACTA ™ 59 chemopreventive agent 59 refractory colorectal cancer 59 inhaled liposomal ciprofloxacin 59 RNAi therapeutic targeting 59 Varespladib 59 Phase Ib clinical 59 antibody MAb 59 Urocidin 59 teriflunomide 59 Dalbavancin 59 haematological cancers 59 CA9 SCAN 59 rALLy clinical trial 59 GVAX R 59 non porcine pancreatic 59 oral prodrug 59 mTOR inhibition 59 Fibrillex 59 PD LID 59 huC# DM4 59 gefitinib Iressa 59 Successfully Completes Phase 59 PRX# 59 Virulizin 59 ulimorelin 59 Apaziquone 59 TKM ApoB 59 Difimicin 59 XL# SAR# 59 ZYBRESTAT 59 PEGylated interferon 59 R sorafenib tablets 59 E2F Decoy 59 Chimigen TM 59 MAXY VII 59 selective modulator 59 SPRYCEL ® 59 histone deacetylase inhibitor 59 L BLP# 59 Marqibo TM 59 AN# novel 59 Anavex #-# 59 antiangiogenic agent 59 ProLindac TM 59 epothilone 59 Hedgehog Pathway Inhibitor 59 dasatinib Sprycel 59 RhuDex R 58 PEG uricase 58 JAK1 58 investigational compounds 58 Tykerb lapatinib 58 Uvidem 58 triggers apoptosis programmed 58 IgG1 monoclonal antibody 58 HCV polymerase 58 non alcoholic steatohepatitis 58 PHX# 58 investigational monoclonal antibody 58 BCR ABL inhibitors 58 rasagiline tablets 58 CB2 selective 58 lumiliximab 58 cetuximab Erbitux 58 Corlux 58 Forodesine 58 tanespimycin 58 Phase #b/#a trial 58 tolevamer 58 OMP #M# 58 Mpex 58 HCV protease inhibitors 58 OHR/AVR# 58 p# inhibitor 58 HepeX B 58 TACI Ig 58 Aganocide ® 58 drug conjugate 58 Bicifadine 58 ganaxolone 58 LEVADEX ™ 58 refractory chronic lymphocytic 58 JAK inhibitors 58 fosbretabulin 58 Curaxin CBLC# 58 oral ridaforolimus 58 polysaccharide polymer 58 Antiangiogenic 58 Hybridon 58 HSP# inhibitor 58 neratinib 58 GSK '# 58 Allovectin 7 ® 58 RenaZorb TM 58 Achieves Primary Endpoint 58 oral antiplatelet 58 Familial Adenomatous Polyposis FAP 58 Genasense ® 58 sodium glucose transporter 58 Tarvacin TM 58 novel therapeutic antibodies 58 RSR# 58 Nanobody 58 TG# [003] 58 Nick Leschly 58 multicenter phase 58 telomerase therapeutic 58 LibiGel ® 58 oral Janus kinase 58 Omapro 58 ZACTIMA 58 GLP toxicology studies 58 Liprotamase 58 Abiraterone acetate 58 glufosfamide 58 Generx ™ 58 BRIM2 58 EECP ® therapy 58 skeletal sarcomere activator 58 ATL# [002] 58 virus HCV protease inhibitor 58 LymphoStat B belimumab 58 dirucotide 58 refractory prostate cancer 58 JZP 58 vinorelbine tartrate 58 Novolimus 58 TransMID TM 58 initiated Phase Ib 58 Fc engineered 58 Alfacell proprietary ribonuclease 58 vemurafenib 58 Fabry Disease 58 Onalta 58 Hedgehog pathway inhibitor 58 cilengitide 58 CRTH2 58 RNAi therapeutic targeting PCSK9 58 selective immunoproteasome inhibitor 58 P#X# antagonist 58 Tasimelteon 58 Inhalation Solution 58 ALN TTR# 58 sorafenib Nexavar 58 Phase 2b clinical trials 58 Perifosine 58 Phase 1a clinical 58 CD# CEA 58 Viprinex TM 58 tramiprosate 58 regorafenib 58 ENMD # 58 pan histone deacetylase 58 TRAIL receptor antibodies 58 selective kinase inhibitor 58 sapacitabine 58 Talabostat 58 Modrenal R 58 MCSP respectively 58 humanized monoclonal 58 Etubics 58 MEK inhibitors 58 SuperAntibody 58 JAK2 inhibitors 58 gemcitabine Gemzar ® 58 phase IIb trial 58 TOCOSOL Camptothecin 58 Dacogen decitabine 58 Solazed ™ 58 novel nucleoside analog 58 antisense drug 58 Lixivaptan 58 adecatumumab MT# 58 CD3 monoclonal antibody 58 Bayer Nexavar 58 Ceflatonin 58 Phase IIa clinical 58 Phase IIa trial 58 TLR9 agonist IMO 58 Therapeutic Vaccine 58 Muraglitazar 58 Elagolix 58 Posiphen TM 58 preclinical efficacy 58 selective androgen receptor modulator 58 VALSTAR TM 58 muscarinic receptor agonist 58 erlotinib Tarceva 58 investigational therapies 58 beta secretase inhibitors 58 Trofex ™ 58 MLN# 58 novel peptide 58 HCD# [002] 58 Cimzia TM 58 LEUKINE 58 anticancer therapeutics 58 hematological indications 58 Ceflatonin R 58 Ecallantide 58 chimeric monoclonal antibody 58 Chronic Myeloid Leukemia CML 58 Lubiprostone 58 JAK2 inhibitor 58 IMC #B 58 Cardio Vascu Grow 58 RGB # 58 dextofisopam 57 highly selective adenosine 57 Cathepsin S 57 metastatic castrate resistant 57 TASKi2 57 TKB# 57 bladder ovarian 57 HepeX B TM 57 PXD# 57 ZEVALIN ® 57 IV APAP 57 preclinically 57 Hsp# Inhibitor 57 TOCOSOL Paclitaxel 57 dermatology biopharmaceutical company 57 cathepsin K inhibitor 57 immunotherapeutic vaccine 57 Vidaza azacitidine 57 MGd 57 Aurora Kinase 57 CRMD# 57 TLR9 agonist 57 ACAPODENE TM 57 miconazole Lauriad 57 Monoclonal antibody 57 mSEPT9 biomarker 57 Sutent sunitinib 57 iSONEP ™ 57 PANVAC VF 57 IMPDH inhibitor 57 acadesine 57 Thalomid ® 57 pralatrexate 57 Junovan TM 57 monoclonal antibody conjugated 57 delafloxacin 57 candidate deforolimus 57 Ziopharm 57 omacetaxine 57 adalimumab Humira 57 accumulate preferentially 57 DCVax R 57 phase Ib 57 DXL# 57 Phase IIa clinical trials 57 diarrhea predominant irritable 57 pomalidomide 57 NEUGENE antisense 57 Cinryze ™ 57 ganetespib 57 Oglemilast 57 EVIZON TM squalamine lactate 57 rhIGF-I/rhIGFBP-3 57 ongoing Phase 1b 57 Aplidin R 57 samalizumab 57 BRAF inhibitor 57 teduglutide 57 Gattex 57 CAMPATH 57 sJIA 57 Voreloxin 57 Perflubutane Polymer Microspheres 57 riociguat 57 Seliciclib 57 Anticalin R 57 preclinical pharmacokinetic 57 6R BH4 57 MDS AML 57 Begins Dosing 57 IAP inhibitor 57 AFREZZA ® 57 Chemokine 57 Specifid 57 Initiates Clinical 57 phase IIb study 57 HCV protease inhibitor 57 Bayer HealthCare Onyx Pharmaceuticals 57 Capesaris 57 entinostat 57 Phase Ib 57 Sipuleucel T 57 anticancer compound 57 OncoVex 57 leading oral taxane 57 Litx 57 Oasmia 57 tafamidis 57 ovarian cancer chronic hepatitis 57 novel immunotherapies 57 indibulin 57 intranasal formulation 57 Vicriviroc 57 Inovio DNA 57 AKT inhibitor 57 Vitaxin 57 Phase 1b clinical 57 factor VIIa 57 induced mucositis 57 Phase Ib study 57 LUNESTA TM 57 candidate CRLX# 57 VA# [002] 57 efaproxiral 57 PEGylated interferon beta 1a 57 anti PlGF 57 Eribulin 57 TEMSO 57 PrevOnco ™ 57 octreotide implant 57 Eculizumab 57 novel L DOS# 57 mRCC 57 atypical hemolytic uremic syndrome 57 ZEFTERA TM Zevtera TM 57 Telatinib 57 DP VPA 57 sterile lidocaine patch 57 nucleoside analog 57 HyperAcute 57 Vandetanib 57 ASONEP 57 Randomized Phase 57 dutogliptin 57 intranasal insulin product 57 PDL# 57 HGS# 57 Balaglitazone 57 Fulvestrant 57 protein kinase inhibitor 57 antisense inhibitors 57 verteporfin 57 Investigational Treatment 57 ELND# 57 ZFP Therapeutics 57 Darinaparsin 57 Kinase Inhibitor 57 inhibit metastasis 57 Cintredekin Besudotox 57 evaluating tivozanib 57 prescribed proton pump 57 renin inhibitors 57 Exelixis XL# 57 oral anticancer 57 Sapacitabine 57 carcinoid syndrome 57 HGS ETR2 57 QLT# 57 cyclophilin inhibitors 57 dimebon latrepirdine 57 investigational hepatitis C 57 phase III isavuconazole 57 somatostatin analogue 57 mitiglinide 57 Exherin TM 57 hormone LHRH antagonist 57 PEP# [003] 57 Phase Ib IIa 57 ThermoDox R 57 sorafenib tablets 57 PNT# 57 XP# XP# 57 Phase 2a trial 57 opioid induced bowel dysfunction 57 Surfaxin LS 57 Tß4 57 Epratuzumab 57 orally bioavailable 57 UVIDEM 57 cell lymphoma CTCL 57 Diabetic Macular Edema DME 57 HER2 positive metastatic breast 57 BCX# 57 Denufosol 57 Meets Primary Endpoint 57 patientswith 57 MGCD# [001] 57 Bucindolol 57 malignant ascites 57 alkylating agent 57 inhibitor RG# 57 drug ISA# 57 BrachySil 57 5 fluorouracil leucovorin 57 pouchitis 57 eniluracil 57 DPX Survivac 57 ocrelizumab 57 Triolex 57 Myelodysplastic Syndrome MDS 57 RH1 57 CINOD 57 Phase IIb trials 57 Pralatrexate 57 sitaxsentan 57 EVIZON ™ 57 Tamibarotene 57 2 methoxyestradiol 57 SILENOR TM doxepin HCl 57 perifosine 57 Harry Palmin President 57 Hsp# inhibition 57 apaziquone 57 GSK# [002] 57 dasatinib Sprycel ® 57 eosinophilic asthma 57 CLL SLL 57 FluCide 57 Rebif ® 57 mTOR inhibitor 57 Azedra 57 HGS ETR1 57 Advaxis Phase 57 relapsed MM 57 goserelin 57 Quinamed 57 BioNumerik 57 TASKi3 57 talactoferrin 57 Onco TCS 57 GLPG# 57 including eniluracil ADH 57 RAPTIVA R 57 NTDDS 57 bortezomib Velcade 57 Glufosfamide 57 Initiates Clinical Trial 57 vascular disrupting agent 57 multitargeted 57 either acutely decompensated 57 INSPIRE Trial Phase III 57 AAG geldanamycin analog 56 PEG PAL 56 Phase Ib Clinical Trial 56 ApoB SNALP 56 oral Factor Xa 56 ReN# 56 MOVIPREP R 56 mGluR5 NAM 56 tivozanib 56 etanercept Enbrel 56 Zenvia ™ 56 GED aPC 56 Apokyn R 56 Collategene 56 pertuzumab 56 XOMA 3AB 56 compound perifosine 56 Neo Kidney Augment ™ 56 CytoFabTM 56 LEVADEX TM 56 randomized controlled Phase 56 Relivar 56 anti angiogenic agents 56 ALN TTR 56 small molecule Hedgehog 56 Pazopanib 56 Combidex 56 Polymer Microspheres 56 PCK# 56 sunitinib Sutent 56 VEGF Trap 56 Anidulafungin 56 mTOR mammalian target 56 pafuramidine maleate 56 IMiDs ® 56 Chemophase 56 VitiGam TM 56 preclinical 56 TPI ASM8 56 monoclonal antibody therapeutics 56 oxypurinol 56 antiangiogenic therapy 56 PI3K/mTOR 56 Chrysalin 56 Phase III clinical 56 hypereosinophilic syndrome 56 cMET 56 AERx iDMS 56 selective estrogen receptor modulator 56 diagnostic biomarker 56 Pirfenidone 56 Phase 2a clinical 56 luliconazole 56 Arcalyst 56 ACAPODENE 56 antimitotic 56 NEBIDO R 56 immuno modulatory 56 Vascular Wrap TM 56 Solzira ™ 56 telomerase inhibitor drug 56 Phenoptin 56 small molecule chemotherapeutic 56 Anturol TM 56 ALK inhibitors 56 unresectable stage 56 bardoxolone methyl 56 Desmoteplase 56 Celator 56 Tarvacin 56 EFAPROXYN 56 A3 adenosine receptor 56 Anturol ® 56 Ridaforolimus 56 TRISENOX 56 midstage trials 56 GALNS 56 Aloxi injection 56 immunosuppressant therapies 56 Ixabepilone 56 ISIS # 56 Vascugel 56 Phase Ia 56 ONCONASE R 56 Nuvion 56 Combination REOLYSIN R 56 metastatic malignant 56 Bayer Onyx 56 squalamine 56 forodesine hydrochloride 56 Zenyaku Kogyo 56 APEX PD 56 Phase #b/#a 56 methylnaltrexone 56 relapsing remitting MS RRMS 56 MET inhibitor 56 relapsed multiple myeloma 56 IMiDs ® compound 56 omiganan 56 Tyrima 56 adenosine A2A 56 VentiRx 56 Avila Therapeutics 56 Triapine R 56 MTP inhibitor 56 RSD# oral 56 LAF# 56 non nucleoside HCV 56 nitric oxide donating prostaglandin 56 blinatumomab 56 Taligen Therapeutics 56 Zemplar Capsules 56 ART# 56 enzastaurin 56 2DG 56 CA4P 56 JAK2 Inhibitor 56 BENLYSTA ® 56 Prodarsan R 56 TheraCIM 56 TEMODAL 56 registrational trial 56 Darusentan 56 Phase III psoriasis 56 vinca alkaloid 56 CytoFab 56 SERMs 56 Bremelanotide 56 Tesetaxel 56 Alemtuzumab 56 Panzem NCD 56 dextromethorphan quinidine 56 siRNAs targeting 56 novel immunotherapeutic 56 Sym# 56 REG2 56 PKC# 56 Empatic TM 56 DCCR 56 oral proteasome inhibitor 56 Enobia 56 BEMA TM Fentanyl 56 Synavive 56 Eniluracil 56 celgosivir 56 Novel Oral 56 initiate Phase IIb 56 cutaneous T 56 Vertex retains 56 sargramostim 56 RNA antagonists 56 Mersana 56 Phase 2b kidney transplant 56 advanced carcinoid 56 romidepsin 56 interferon gamma 1b 56 Civacir 56 Olaparib 56 drug NP2 Enkephalin 56 imatinib Gleevec ® 56 phase IIb 56 Phase 2b study 56 ionotropic glutamate receptor antagonists 56 aldehyde dehydrogenase ALDH2 deficiency 56 phase IIb III 56 novel oral anticoagulant 56 faropenem medoxomil 56 Rescula 56 treat chronic sinusitis 56 Ambrisentan 56 Gelclair 56 OncoVEX 56 INTEGRILIN ® 56 Vicinium TM 56 INCB# [002] 56 Tyzeka Sebivo 56 therapeutic monoclonal antibodies 56 fluoropyrimidine 56 Phase IIb clinical 56 afamelanotide 56 NeutroSpec TM 56 Glypromate 56 Chemokine Therapeutics 56 Phase 2b trial 56 Evoltra TM 56 PEGylated Fab fragment 56 Adnectin 56 AzaSite Plus 56 BNC# 56 OMNARIS HFA 56 Syncria R 56 bavituximab monotherapy trial